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PRINCIPLES AND PRACTICE
HAEMOPHILIA, PAST AND PRESENT
by
Dr. S.H. Davies
lately Consultant Haematologist; Royal Infirmary of Edinburgh
INTRO D U CT IO N
The term haemophilia, meaning “lover of 
blood", was coined comparatively recently in the 
long history of bleeding disorders, having been 
first used in the early 19th century. Then it 
defined a bleeding disorder which was transmitted 
by certain unaffected females to some of their 
sons. Now, as a result of the enormous increase in 
scientific knowledge developed in the interim, 
haemophilia can be defined more precisely as a 
coagulation disorder transmitted in a sex-linked 
recessive manner and primarily expressed in males, 
in which the level of factor V I II  clotting (or 
biological) activity in the blood is reduced below 
normal because some of the precursor molecules, 
(named immunological factor V III),  are function­
ally abnormal and cannot be converted to clotting 
factor V III.  The clinical grade of severity of the 
disorder breeds true and correlates well with the 
amount of circulating clotting factor V III,  severely 
affected haemophiliacs having less than 1%, 
moderately affected between 1 and 5%  and mildly 
affected between 5 and 50%. The normal range 
is 50 -  200%.
H A E M O PH IL IA  IN H IST O R Y
The first recorded references to haemophilia 
in man are probably to be found in Jewish writings 
of the 2nd Century A.D. where families are 
mentioned in which more than one male child died 
of excessive bleeding following ritual circumcision. 
The disorder also occurs in animals and probably 
first began in placental mammals through genetic 
mutation about 50 million years ago.
The severely affected patient bleeds 'spont­
aneously' in response to the ‘microtrauma of 
living' and this grave gene deficiency was 
usually lethal in olden times before the 
reproductive age was reached. We therefore 
believe that the severe grade of the disorder 
was maintained in man by spontaneous genetic 
mutation and the mutation rate has been 
estimated at about 2 x 10-5 (W.H.O., 1972).
The history of haemophilia makes fascinating 
reading and the reader interested in a more 
detailed study of the subject is advised to read the 
excellent article by Ingram (1976). Apart from the 
methodic early clinical studies on the subject and 
the more recent scientific investigations recorded 
by Ingram, it is interesting to speculate on the role 
the disorder has played in European and Russian 
political history. Queen Victoria is thought to have 
acquired a carrier state at conception through 
genetic mutation, which was first recognised with 
the birth of her eighth child Leopold who was a 
severe haemophiliac. More significantly she 
produced at least two carrier daughters in her large 
family. One of these, Beatrice, transmitted the 
carrier status to her daughter Victoria Eugenie who 
married Alfonso X III,  King of Spain, and at least 
two of their five sons were severe haemophiliacs. 
Through Alix, whose daughter Alice married Tsar 
Nicholas II of Russia, was born in 1904 the 
severely affected haemophiliac, and only son, 
Alexis. The inability of doctors to prevent, or even 
alleviate, the repetitive painful joint bleedings 
associated with this disorder in the boy, may
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have contributed to the evil influence that 
the monk Rasputin acquired over the unhappy 
Royal parents for the Tsarina had great faith in 
his healing powers. Isolated from everyday affairs 
by their preoccupation with their son's disability, 
the Royal parents may well have contributed to 
the tragic downfall and death of the family in the 
Bolshevik revolution. The drama of haemophilia 
is vividly portrayed in two novels by R.K. Massie 
("Nicholas and Alexandra", 1968) and Dorothy 
Sayers ("Have his Carcase", 1932).
PRESENTATION AND  NATURE
Classical haemophilia (factor V III deficiency) 
has to be distinguished from von Willebrand's 
disease, and particularly from Christmas disease 
(factor IX  deficiency) with both of which it shares 
some common clinical and laboratory features. 
The distinction, made as recently as 1952 in the 
case of Christmas disease, is important not least 
because modern clotting factor replacement 
therapy is reasonably specific for each disorder 
and the products used are not interchangeable.
The hallmark of a bleeding disorder is the per­
sistence rather than the rate of blood loss. The 
typical haemophiliac is therefore a male in whom 
the clinical symptoms correlate well with the 
degree of his clotting factor deficiency. The 
severely affected patient, with less than 1% factor 
V III, bleeds 'spontaneously', that is without appar­
ent injury, the moderately affected in response to 
minor injury, but not spontaneously and the 
mildly affected in response to minor injury, but 
not spontaneously and the mildly affected only 
to moderate injury. More than 90% of bleedings 
in the severely affected patient occur into joints, 
and the knees, ankles and elbows are most 
frequently affected, though the reason why these 
particular joints should be involved is not known. 
The unpredictability of such bleedings in the 
severe haemophiliac with apparent normality in 
between episodes had a profound psychological 
effect on him in the days before modern factor 
replacement therapy became available to abort the 
bleeds in an early stage. Such joint bleeds, if un­
treated, produce intense pain and immobility and 
will eventually, when repeated sufficiently often, 
result in joint damage, permanent limitation of 
movement and finally crippling haemarthritic 
deformity. Less commonly occurring bleeds into
muscles and tissue compartments can likewise, by 
their pressure effects, cause muscle necrosis or 
nerve damage and hence loss of function. 
Haemorrhage into a closed cavity such as the 
skull can cause brain damage and often death. 
Intracranial haemorrhage is now one of the 
commonest causes of death in this group of 
patients.
Classical haemophilia is the commonest of the 
single clotting factor disorders in Great Britain 
and has an approximate incidence of 6 per 
100,000 in the population. About half of these 
patients are severely affected and the remainder 
are about equally distributed in the moderately 
and mildly affected grades. Whilst there is reason 
to believe that even some severely affected haemo­
philiacs have not yet been diagnosed and recorded, 
there is even stronger evidence that more of the 
moderately and mildly affected patients have 
escaped the net. These latter groups do not mani­
fest their disability so obviously as the severely 
affected patients, particularly as the accepted 
blood loss due to trauma in normal males varies 
widely.
Christmas disease (factor IX  deficiency) is about 
one fifth as common in the population as haemo­
philia.
M ANAG EM ENT
The factor V III molecule is unstable in solution; 
it and factor V, only rarely congenitally deficient, 
are known as the 'labile' clotting factors. It has a 
half-life at blood heat in vitro and in vivo of 8 — 
12 hours, whereas that of factor IX  is 18 — 24 
hours. It is ofen not appreciated that primary 
normal wound healing which, depending on the 
size of the wound, the presence or absence of 
infection and the nutritional state of the patient, 
may take up to 14 days to complete requires 
adequate levels of factor V III and the other 
clotting factors in the blood throughout. Failure 
to meet these needs will result in immediate or 
delayed wound bleeding according to the time in 
the healing process that it occurs. The quantity of 
factors needed is roughly proportional to the size 
of the wound. Less explicable is the fact that 
'spontaneous' injury needs less clotting factors 
for healing than does overt trauma of apparently 
similar degree. The mildly affected haemophiliac
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who has some endogenous production of factor 
V III  can therefore cope unaided with mild trauma 
as can the moderately affected patient with 
minimal trauma, but the severely affected 
haemophiliac will often bleed abnormally in 
response to the occult trauma 'of being'. The 
principle of treatment of injury in these patients is 
to raise the deficient clotting factor to a safe blood 
level by exogenous means and to so maintain it 
until healing has been achieved.
In the 'spontaneous' joint bleed this may mean 
obtaining a 'once only' peak of 20% whereas for 
more severe trauma, for example operative 
surgery, a pre-operative level of at least 60%  will 
usually be required, and thereafter the trough level 
must not fall below 20% until late in healing. To 
achieve this goal repetitive infusions of factor 
V III  as often as six-hourly may be necessary for 
much of the healing period. The greater the threat 
of re-bleeding, for example in intracranial injury, 
the longer is it wise to sustain a haemostatic level 
of the clotting factor in the blood. Meticulous 
surgical haemostasis together with wound rest by 
splintage etc. minimises factor V III  requirements 
and is always advocated in the management of 
injury in haemophilia.
The improved management of severe haemo­
philia is the result of four main factors: (i) precise 
diagnosis, (ii) early treatment of bleeding episodes, 
(iii) a better understanding of factory V III  require­
ments as discussed above and (iv) the availability 
of stable, concentrated preparations of clotting 
factor V III.  Clearly it is impossible to raise and 
maintain the factor V III  level of a severe haemo­
philiac from less than 1% to at least 60% with 
whole blood or even plasma without causing circu­
latory overload and heart failure. The availability 
of such concentrated factor V III products has 
therefore revolutionised the management of 
haemophilia.
The History of Replacement Therapy
The history of blood transfusion in man is 
much shorter than that of haemophilia. It began 
in the 17th century, initially with the use of 
animal as well as human blood, and usually in 
either case with disastrous results to the patient. 
It was mainly due to the discovery, first by Land- 
steiner of the ABO  blood groups, and then by 
Weiner of the Rhesus (Rh) groups, in the last
fifty years that blood transfusion has become safe 
and practicable.
The management of bleeding battle casualties 
in World War II soon brought an appreciation of 
the urgent need for early restoration of the intra- 
vascular deficit by an isosmotic, colloid containing 
fluid even without red cells, at least until the loss 
of these became very severe. The separation of 
plasma from whole blood by centrifugation 
followed by the preparation of a dried, and hence 
stable, product met this need. Such a product was 
also easy to reconstitute and administer in forward 
battle areas, and did not require the skilled tech­
nical compatibility matching which is always 
desirable, and often essential, when whole blood 
is used. By this time Macfarlane in Oxford and 
other workers elsewhere, had also realised that 
only intravenous factor replacement therapy 
would satisfactorily and safely control bleeding in 
the haemophiliac.
The knowledge gained during the War years in 
the preparation, handling and use of plasma stimu­
lated further exploration of this product for its 
more specific component fractions. This had two 
main objects, namely (i) to produce more specific 
products of high potency which would make 
possible sustained, intensive replacement therapy 
in patients, and (ii) to make more economic use 
of blood which, in Great Britain, is obtained from 
voluntary donors who have to be allowed a mini­
mum period of four months to make good the 
deficit produced by the giving of one whole blood 
donation.
Factor V III  requirements at that stage, because 
of the instability of the molecule in vitro, were 
best met by using fresh plasma (within no more 
than four hours of blood donation) which was 
inconvenient. However, the factor V III  activity in 
such plasma could be preserved for at least three 
months either by immediately deep freezing it to 
not less than -20° C or by freeze drying it.
Unfortunately neither of these measures solved 
the problem of the unacceptable volume it was 
necessary to transfuse to achieve and maintain 
an adequate haemostatic level of factor V III  in 
a severe haemophiliac for other than trivial bleeds.
The next logical sequence was plasma fraction­
ation. After the pioneer work in this field of 
Cohn et al (1946), crude concentrates of human
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and animal products were produced in various 
European and American centres in the early 
1950's and used w ith increasing success in the 
management o f the more serious and major 
bleeding episodes in haemophiliacs whether they 
were spontaneous or traumatic, accidental or 
elective in origin. The species specificity of the 
highly potent concentrates obtained from the pig 
and the cow limited their use in man because of 
the sensitisation and thence severe reactions they 
eventually induced in the recipient, but they 
fu lfilled  an important interim role where large 
dosage o f factor V III was needed until the human 
product could be adequately refined. This latter 
achievement dates from a chance observation 
made in America by Judith Pool and her 
colleagues (1965). She noticed that when human 
plasma was deep frozen at -20°C and then slowly 
thawed, the large plasma protein molecules, factor 
V III (m. w t about 2 x 106) and to  a lesser degree 
fibrinogen (factor I, m. w t 560,000), would at 
4°C remain fo r a time as a sludge or cryopreci- 
pitate whilst the other plasma proteins went into 
solution. By careful removal of most of the liquid 
supernatant the sludge could be harvested and 
then stored stable deep frozen at not less than 
-20°C in the little  remaining plasma until required 
fo r use. It could then be dissolved as required in 
the retained plasma by controlled thawing at 
blood heat (37°C) and injected intravenously at 
once. Comparatively high doses o f factor V III 
could thus be obtained in an acceptably small 
plasma volume by pooling as many of these cryo- 
precipitate donations as were necessary.
The theoretical and practical disadvantages of 
such cryoprecipitate were (i) the time consuming 
skill needed in preparation o f each individual pack, 
(ii) the variability o f factor V III levels in the 
normal donors and the manipulative loss in 
preparation, (iii) the need fo r controlled 
temperature thawing (37°C) to  avoid factor V III 
loss immediately prior to  use and (iv) the need to 
enter several packs w ith its attendant infection 
risk to  obtain a sufficient dose of factor V III fo r 
therapeutic use.
On the other hand despite the technical, organ­
isational and economic difficulties o f harvesting 
large quantities of whole blood, separating and 
deep freezing the plasma immediately, storing and 
transporting it  deep frozen to a central large scale
fractionation unit, and the technical difficulties 
of large scale fractionation w ithout loss o f potency 
of the components, cryoprecipitate has been an 
important interim advance in the treatment of 
haemophilia and it still remains so today. Never­
theless, at various centres in Britain (Oxford, 
Elstree, Edinburgh) large scale plasma fraction­
ation is a reality and the quality and quantity of 
the products, available, not least o f factor V III, 
are increasing and in some cases (e.g. factor IX) do 
meet all the present day requirements. The freeze 
dried factor V III so produced has many advantages 
over the stalwart cryoprecipitate.' First, it  is 
produced from a large, pooled, plasma batch and 
equal aliquots o f the finished product are freeze 
dried in individual vials; thus the dose is constant 
in each vial from any batch. Secondly, by standard 
random sampling the vials can be checked for 
potency and sterility and duly labelled w ith this 
information. Thirdly, the product is stable fo r a 
considerable time if kept at 4°C, and it can be re­
constituted in a small volume of  sterile water 
immediately prior to  use to  give a known factor 
V III dose which usually has a potency o f at least 
twenty times that of an equal volume o f fresh 
plasma.
The present aim is to  produce dried products 
of ever greater potency w ith acceptable recovery 
loss in manufacture and in such quantities that 
they w ill meet all needs o f haemophiliacs fo r 
factor V III.
Management today
How has the management o f haemophilia 
changed and kept pace w ith the blood product 
development? First, it  has become more aggressive; 
that is treatment o f spontaneous bleeding, 
commonly into joints, is given earlier and is more 
effective so that bleeding is arrested before 
distention and pain occur, and temporary 
disability, permanent damage and deform ity are 
minimised or prevented. This results in less time 
lost from school, work or leisure activities. 
Secondly, major surgery, whether fo r disorders 
that may beset us all, such as the complications of 
peptic ulcer or extensive dental caries, or fo r those 
peculiar to  the haemophiliac, such as jo in t 
deformities from  past haemarthroses, has been 
made much safer and can now be undertaken 
electively and not only as a desperate life-saving
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measure. For these aims to achieve fruition other 
associated developments have been necessary. 
Haemophilia Centres have been established and 
developed in major hospitals so that precise 
diagnoses can be made and patients counselled, 
advised and instructed. At these Centres 
specialised out-patient treatment is available on a 
24-hour basis and the haemophiliac can report 
direct to the Centre using the Ambulance Service 
or his own 'car for the disabled' to get there. 
Joint bleeds etc. can thus be treated at a very early 
stage and the haemophiliac, if sufficiently 
competent, can be taught self-injection of the 
factor V I I I  made available at the Centre 'on 
demand'. When he is fully trained, and when 
adequate dried factor V I I I  supplies are available, 
he can change to the Home Treatment programme. 
He will then be issued with a limited supply of 
dried factor V III  with which he can treat joint 
bleeds — the bugbear of the severe haemophiliac's 
life — at home and thus save time and trouble and 
gain independence. Since 95%  of all factor V III  
used by a severe haemophiliac is for such bleeds, 
the advantages of home therapy are obvious. For 
bleeds other than into joints, out-patient manage­
ment at the Centre, or occasionally in the Ward, is 
still advisable and the haemophiliac must not 
attempt such treatment at home.
The future
Whilst present progress has revolutionised the 
life of the severe haemophiliac, given him self- 
confidence and a much greater degree of 
independence, it has not cured him. A t present we 
know of no means of achieving this. Perhaps as 
supplies of factor V III  improve still further, we 
will be able to offer him prophylaxis, but the short 
factor half-life would probably necessitate twice 
daily self-infusion of factor V I I I  rather like an 
insulin-dependent diabetic though using the intra­
venous route. However, about 10% of haemo­
philiacs develop a neutralising 'antibody'to factor 
V I I I  which is not dose related, and at present is 
causally not understood. In some it persists in the 
plasma indefinitely and in others it wanes if not 
provoked by further therapy, but in all it con­
stitutes a bar to replacement therapy, either 
totally or save in urgent circumstances. Manage­
ment of these patients is at present not very satis­
factory even though blood products with 'factor 
V I II  bypassing activity' have some beneficial
use. We can, however, hope for a radically 
different approach to the problem of haemophilia. 
It is possible even now to sex the foetus in utero 
accurately in early pregnancy, and where the 
mother is a known or potential carrier of the 
disorder this may be advisable; however, the 
procedure is associated with a small abortion 
loss. Hopefully in the near future it will be 
possible to measure the factor V III  level in the 
foetus accurately and thus offer therapeutic 
abortion of an affected male foetus if desired.
The investigation of suspected female carriers 
of haemophilia is becoming more specific, based 
upon the dissociation of the levels of clotting and 
immunological factor V III  in the blood of those 
positive for the trait, but it is not yet wholly 
reliable. An entirely new approach to the manage­
ment of haemophilia depends upon using an 
exogenous stimulus to induce a temporary increase 
in endogenous production of factor V III.  Deamino- 
D-arginine vasopressin (DDAVP) given intra­
venously or as snuff is used for this purpose but 
is effective only in the moderately or mildly 
affected patient (Mannucci et al, 1975). And so 
the search for better products, more effective 
and simpler treatment, prophylactic rather than 
therapeutic, goes on. Selective abortion as a 
preventative measure is never likely to overcome 
the perpetuation of the disorder through spon­
taneous genetic mutation and hence the goal must 
ultimately be to find a cure. This still seems to be 
a long way off, but progress towards it accelerates.
The Haemophilia Society
What have haemophiliacs done to help 
themselves? In the early 1940's in Britain they 
formed their own Haemophilia Society and this is 
now linked with other similar societies elsewhere 
in the world in the World Federation of Haemo­
philia. Through their Society, and as a minority 
group in the population, they have helped to 
dispel fear and ignorance of the disease and this 
has improved their opportunities for better 
medical care, schooling, employment and leisure. 
The Society has, through organised meetings and 
its literature, helped parents of newly diagnosed 
haemophiliacs and the effected children 
themselves, to adjust and adapt to the disability 
and to lead a fuller, more balanced life. It has 
provided funds for research and has agitated
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and helped to make Governments understand the 
needs of all handicapped people, and of those 
with haemophilia in particular.
And so whilst haemophilia and its problems 
are so much better understood and managed than
in those far off days of the Rabbinic references to 
exsanguination of ritual circumcision, there is still 
much to be done and the contributions made in 
this field in the future, as in the past, will add to 
as much as they derive from, the advances made 
in medicine in their widest sense. 
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